Last reviewed · How we verify
Meropenem and Pralurbactam
Meropenem is a broad-spectrum beta-lactam antibiotic that kills bacteria by inhibiting cell wall synthesis, while pralurbactam is a beta-lactamase inhibitor that protects meropenem from enzymatic degradation by resistant bacteria.
Meropenem is a broad-spectrum beta-lactam antibiotic that kills bacteria by inhibiting cell wall synthesis, while pralurbactam is a beta-lactamase inhibitor that protects meropenem from enzymatic degradation by resistant bacteria. Used for Complicated intra-abdominal infections, Complicated urinary tract infections, Hospital-acquired and ventilator-associated bacterial pneumonia.
At a glance
| Generic name | Meropenem and Pralurbactam |
|---|---|
| Sponsor | Qilu Pharmaceutical Co., Ltd. |
| Drug class | Beta-lactam antibiotic with beta-lactamase inhibitor |
| Target | Penicillin-binding proteins (meropenem); serine beta-lactamases (pralurbactam) |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
Meropenem works by binding to penicillin-binding proteins and disrupting bacterial cell wall cross-linking, leading to cell lysis and death. Pralurbactam inhibits serine beta-lactamases (including extended-spectrum and carbapenem-resistant variants), preventing the inactivation of meropenem and restoring its activity against resistant gram-negative and gram-positive pathogens.
Approved indications
- Complicated intra-abdominal infections
- Complicated urinary tract infections
- Hospital-acquired and ventilator-associated bacterial pneumonia
- Infections caused by carbapenem-resistant Enterobacteriaceae (CRE)
Common side effects
- Diarrhea
- Nausea
- Headache
- Phlebitis at injection site
- Elevated liver enzymes
Key clinical trials
- A Study to Evaluate the Efficacy and Safety of Meropenem and Pralurbactam in HABP/VABP (PHASE3)
- Study to Assess the Efficacy and Safety of Meropenem and Pralurbactam in Carbapenem-Resistant Enterobacteriaceae Infections (PHASE3)
- Study to Assess the Efficacy and Safety of Meropenem and Pralurbactam in CIAI (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Meropenem and Pralurbactam CI brief — competitive landscape report
- Meropenem and Pralurbactam updates RSS · CI watch RSS
- Qilu Pharmaceutical Co., Ltd. portfolio CI